AstraZeneca's lung cancer AZD9291 shrinks tumor in 50 percent of patients during trial AstraZeneca introduced a new experimental drug that shrank tumors in 51 percent of cancer patients. The company has dubbed it as the "new great white hope" in its battle not only against cancer but also against Pfizer's planned takeover. by Anne Francis